AVITA Medical issues 387,716 shares to Perceptive

Q: How many shares did AVITA Medical issue to Perceptive in the warrant exercise?

AVITA Medical issued 387,716 shares to Perceptive on October 28, 2026, after withholding 112,284 shares for the exercise price in a cashless exercise.

AVITA Medical lodged the related disclosure on the Australian Securities Exchange on November 2, 2026, under ASX listing rules.

Available on EDGAR 11/02/2026 - 04:32 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:32 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

AVITA Medical, Inc. (RCEL) reported that Perceptive Credit Holdings V, LP exercised a warrant for up to 500,000 shares on October 26, 2026, through a cashless exercise. The company withheld 112,284 shares for the exercise price and issued 387,716 shares to Perceptive on October 28, 2026.

The warrant was issued on June 5, 2026, under a Credit Agreement and Guaranty dated January 13, 2026.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Maximum warrant shares: 500,000 shares Shares withheld: 112,284 shares Shares issued: 387,716 shares

3 metrics

Maximum warrant shares 500,000 shares Maximum shares for which the warrant was exercisable

Shares withheld 112,284 shares Withheld for the exercise price on October 26, 2026

Shares issued 387,716 shares Issued to Perceptive on October 28, 2026

Key Terms

cashless exercise, Warrant, Credit Agreement and Guaranty

3 terms

cashless exercise financial

"via a cashless exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Warrant financial

"exercise of the Warrant"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

Credit Agreement and Guaranty financial

"pursuant to that certain Credit Agreement and Guaranty"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did AVITA Medical issue to Perceptive in the warrant exercise?

AVITA Medical issued 387,716 shares to Perceptive on October 28, 2026, after withholding 112,284 shares for the exercise price in a cashless exercise.

When was the Perceptive warrant issued and what agreement governed it?

The warrant was issued on June 5, 2026, under a Credit Agreement and Guaranty dated January 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): November 02, 2026

    

AVITA Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39059	85-1021707
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

28159 Avenue Stanford Suite 220
Valencia, California		91355
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 661 367-9170

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	RCEL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 2, 2026, the Company lodged certain filings on the Australian Securities Exchange (the "ASX") disclosing the exercise by Perceptive Credit Holdings V, LP ("Perceptive") of the warrant certificate issued by the Company to Perceptive on June 5, 2026 (the “Warrant”). As previously disclosed, the Warrant was issued pursuant to that certain Credit Agreement and Guaranty, dated January 13, 2026, by and between Perceptive and the Company and was exercisable for up to 500,000 shares of Company common stock. Perceptive exercised the Warrant on October 26, 2026 via a cashless exercise whereby the Company withheld 112,284 shares covered by the Warrant in respect of the exercise price and issued the remaining 387,716 shares to Perceptive on October 28, 2026.

The filings were lodged on the ASX pursuant to ASX listing rules.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			AVITA Medical, Inc.

Date:	November 2, 2026	By:	/s/ David O'Toole
			Name: David O'Toole Title: Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document